Evidence map›Paper›PMID 31115583›Full record

ArticleOncology reports2019

miR‑767‑5p inhibits glioma proliferation and metastasis by targeting SUZ12.

Jiale Zhang, Shuo Xu, Jia Xu, Yangyang Li, Jie Zhang, Jian Zhang, Xiaoming Lu

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. International journal of molecular sciences · 2024
    Article
  4. Review
  5. Review
  6. Review
  7. Targeted MicroRNA Profiling in Gastric Cancer with Clinical Assessement.Balkan journal of medical genetics : BJMG · 2021
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Identification and Expression of Several Circular RNAs and Knockdown of hsa_circ_0005556 Exerts Oncogenic Functions by miR-767-5p in Gastric Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jiale ZhangDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Shuo XuDepartment of Intensive Care Unit, Zhenjiang First People's Hospital, Zhenjiang, Jiangsu 212002, P.R. China.
Jia XuDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Yangyang LiDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Jie ZhangDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Jian ZhangDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Xiaoming LuDepartment of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Jiangsu Province Hospital · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A growing body of evidence implicates aberrant expression of microRNAs (miRNAs) and dysregulation of mRNA translation in the development and growth of cancer cells. However, little is known about the mechanisms of action of miRNAs in glioma, the most common form of adult‑onset malignant brain tumor. In the present study, the expression and function of miR‑767‑5p were examined in human glioblastoma multiforme (GBM) tissue specimens and cell lines. miR‑767‑5p expression levels were analyzed by quantitative reverse‑transcription PCR; cell proliferation was assessed by CCK‑8, colony formation and 5‑ethynyl‑2'‑deoxyuridine (EDU) assays; the cell cycle phase and apoptosis were detected by flow cytometry; and cell invasiveness was analyzed using wound healing and Transwell invasion assays. It was revealed found that miR‑767‑5p was significantly upregulated in GBM tissues (n=18) compared with normal brain tissues (n=8) and in 6 GBM cell lines compared with normal human astrocytes. Ectopic expression of miR‑767‑5p suppressed proliferation, colony formation, and migration, and promoted cell cycle arrest and apoptosis in GBM cell lines in vitro, and inhibited GBM tumor growth in a mouse xenograft model. Bioinformatics analysis identified the PRC2 component suppressor of zeste‑12 (SUZ12) as a putative target of miR‑767‑5p. Co‑transfection of miR‑767‑5p inhibited the activity of a luciferase reporter construct driven by the wild‑type 3' untranslated region of SUZ12 mRNA, but this was abolished by mutation of the putative miR‑767‑5p‑binding sites. Consistent with the possibility that miR‑767‑5p acts by regulating SUZ12 expression, it was revealed that the inhibitory effects of miR‑767‑5p on GBM cell phenotypes were reversed by overexpression of SUZ12. Our results indicated that forced upregulation of miR‑767‑5p may represent a novel therapeutic strategy for glioma patients by targeting SUZ12.

Indexed as

3' Untranslated RegionsAnimalsBrain NeoplasmsCell Line, TumorCell MovementCell ProliferationDown-RegulationGene Expression Regulation, NeoplasticGliomaHumansMaleMiceMicroRNAsNeoplasm MetastasisNeoplasm ProteinsNeoplasm Transplantation3' Untranslated RegionsMicroRNAsMIRN-767 microRNA, humanNeoplasm ProteinsPolycomb Repressive Complex 2SUZ12 protein, humanTranscription Factors

Identifiers

PMID31115583
PMCPMC6549087
OpenAlexW2945029731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.